Biophytis is a French clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases (lead development program is Sarcopenia, Biophytis is on track to initiate a Ph3 program), including severe respiratory failure in patients suffering from COVID-19 (Ph2/3 being completed with EUA targeted 2022).​

Funding: Looking for Public Investors